Neuroblastoma

Herpes Simplex Virus Delivers Vaccine To Tumor Cells

Published in Gene Therapy Weekly, March 15th, 2001

by N.R. Saltmarsh, staff medical writer -- Inoculating solid tumors with genetic material is a promising concept with a common stumbling block - delivery to the targeted cells.

Now researchers may have found a solution using a modified version of the herpes simplex virus as a carrier for murine B7-1.

"Although the B7 family is known to be the most potent of the co-stimulatory molecules, gene transduction of B7 alone has not been effective in inducing anti-tumor immunity in nonimmunogenic tumors by ex vivo methods, much less in vivo," wrote T. Todo and colleagues in Cancer Research.

The researchers used defective herpes...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Gene Therapy Weekly

Source: Gene Therapy Weekly (2001-03-15)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry